NCT06200402 is a NA clinical trial of Antibiotic loaded in Proximal Femoral Fractures, sponsored by Università Vita-Salute San Raffaele.

Who is sponsoring NCT06200402?

NCT06200402 is sponsored by Università Vita-Salute San Raffaele.

What drugs are being tested in NCT06200402?

Interventions in NCT06200402: Antibiotic loaded, Placebo.

What condition does NCT06200402 study?

NCT06200402 studies Proximal Femoral Fractures.

Is NCT06200402 still recruiting?

NCT06200402 is currently status unknown. Last updated 11 January 2024.

Last reviewed 2024-01-11 · How we verify

NCT06200402

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antibiotic-Loaded Cement Versus Non-Antibiotic-Loaded Cement in Hip Prosthesis Surgery for Proximal Femur Fractures

Status unknown NA Last updated 11 January 2024

What this trial tests

NA trial testing Antibiotic loaded in Proximal Femoral Fractures in 450 participants. Status unknown.

Timeline

1 July 2023

Primary endpoint
1 December 2023

30 December 2025

Quick facts

Lead sponsor	Università Vita-Salute San Raffaele
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	450
Start date	1 July 2023
Primary completion	1 December 2023
Estimated completion	30 December 2025
Sites	1 location across Italy

Drugs / interventions tested

Antibiotic loaded — full drug profile →
Placebo

Conditions studied

Proximal Femoral Fractures — all drugs for Proximal Femoral Fractures →

Sponsor

Università Vita-Salute San Raffaele — full company profile →

Who can join

Adults 65 to 100, any sex, with Proximal Femoral Fractures. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to determine if antibiotic-loaded cement reduces post-surgery infection rates compared to non-antibiotic cement. The trial involves 450 elderly patients with specific hip fractures, assessing infection incidence, implant stability, and associated costs. This randomized, blinded study is conducted by IRCCS Ospedale San Raffaele.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Università Vita-Salute San Raffaele trials

Trials by the same sponsor.

NCT07274384 — Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial · Phase 2 · not yet recruiting
NCT06716502 — A New Portable Device for Non-invasive Ventilatory Support · NA · recruiting
NCT05982496 — 18F FES-PET/MRI for Tailoring Treatment of Luminal a and Lobular Breast Cancer · NA · not yet recruiting
NCT06487091 — Platelet Function and Impella Support · recruiting
NCT06538155 — Technological and Patient-tailored Innovations for Maximizing Effectiveness of Cardiac Arrest Resuscitation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06200402 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Università Vita-Salute San Raffaele
Last refreshed: 11 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06200402.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing